Our previously published ALK-directed ADC demonstrated proof-of-concept in neuroblastoma but was limited in clinical translation due to a lack of potent and sustained efficacy with a thienoindole (TEI) payload29 at doses higher than clinically relevant ADC dosing33. This evidence concerns the gene ALK and neuroblastoma.